Cmed nabs £5m growth cap investment
Scottish Equity Partners has made a £5m growth capital investment in Cmed Group, a Horsham-based provider of clinical research data services to the pharmaceutical and biotech industries.
Apax sued by co-founder
One of the three co-founders of Apax Partners, Maurice Tchenio, is suing the buy-out house over the split of fees and profits in Europe since 2001.
NSEI leads £1.5m Illumix investment
NorthStar Equity Investors has led a £1.5m (€1.8m) funding round for Surrey-based software company Illumix Software.
Welsh trio back View Holographics
Animated holographic technology developer View Holographics has received a £500,000 (€625,000) investment from Welsh business angel network Xenos, Finance Wales and the Welsh Assembly Government
Buyout bosses call the bottom of the market
The next private equity mega deal is at least three years away, according to a poll of European general partners conducted by Real Business’s sister magazine, Real Deals.
Glide Pharma in the money
Oxford-based pharmaceutical company Glide Pharma has attracted £2.2m from Oxford Technology VCTs in a fourth round of funding.
Darling produces bank rescue plan
The government has unveiled details of a rescue package of up to £50bn, designed to free up the UK banking system and get banks lending to each other again.
IQ Capital backs Phonetic Arts
Speech technology company Phonetic Arts will use its first round of funding from IQ Capital to continue to develop its products and increase market share.
Faith merges with Envy
Faith Shoes, a former Bridgepoint portfolio company, has been sold to Scottish retail entrepreneur John Kinnaird and distressed company investment fund Agilo.
Gymbox attracts more cash from private equity
Hotbed has backed UK fitness club operator Gymbox with a further £2.1m (€2.6m) of funding.
Floors-2-Go saved by brother entrepreneurs
Robert and Richard Hodges, part of the Hodges flooring and carpeting dynasty, have bought troubled retailer Floors-2-Go from administrator Kroll for an undisclosed sum.
Funding grows for Serentis
Cambridge-based biopharma group Serentis has raked in £10m in a second tranche of a series A round of funding, from Adamant Ventures and other existing investors.